1Fung J J, bu-Elmagd K, Todo S, et al. Overview of FK506 in transplantation [ J]. Clin Transpl, 1990,115-121.
2Andreoni KA, Brayman KL, Guidinger MK, et al. Kidney and pancreas transplantation in the United States, 1996-2005 [ J]. Am J Transplant, 2007,7 : 1359-1375.
3Liu EH, Siegel RM, Harlan DM, et al. T cell-directed therapies : Lessons learned and future prospects [ J ]. Nat lmmunol, 2007,8 : 25-30.
4Myers BD, Ross J, Newton L, et al. Cyclosporine-associated chronic nephropathy[ J]. N Engl J Med ,1984 , 311: 699-7 05.
5Murray BM, Paller MS,Ferris TF. Effect of cyclosporine administration on renal hemodynamics in conscious rats[ J]. Kidney lnt, 1985,28:767-774.
7Bollee G, Anglicheau D, Loupy A,et al. High-dosage intravenous immunoglobulin-associated macrovacuoles are associated with chronic tubulointerstitial lesion worsening in renal transplant recipients [ J ]. Clin J Am Soc Nephrol, 2008,3 : 1461-1468.
8Ponticelli C. De novo thrombotic microangiopathy. An underrated complication of renal transplantation[ J]. Clin Nephrol,2007 ,67 :335-340.
9Lopez-Ongil S, Saura M, Rodriguez-Puyal D, et al. Regulation of endothelial NO synthase expression by cyclosporin A in bovine aortic endothelial cells [ J ]. Am J Physiol, 1996,271 :H1072-H1078.
10Djamali A. Oxidative stress as a common pathway to chronic tubulointerstitial injury in kidney allografts [ J ]. Am J Physiol Renal Physiol, 2007,293 : F445- F455.
2Dudley C, Pohanka E, Riad H, et al. Mycophenolate mofetil substitution for cyclosporinc a in renal transplant recipients with chronic progressive allograft dysfunction: the Creeping Creatinine Study. Transplantation, 2005,79 (4) : 466 - 475.
3Pilmore HL, Dittmer ID. Calcineurin inhibitome phrotoxicity: reduction in dose results in marked improvement in renal function in patients with coexisting chronic allograft nephropathy. Clin Transplant,2002,16(3) : 191 - 195.
4Martins L, Ventttra A, Branco A, et al. Cyclosporine versus tacrolimus in kidney transplantation: are there differences in Nephrotoxicity? Transplantation Proc, 2004, 36 (4): 877 - 879.
5Wang T, Donahoe PK, Zervos AS. Specific interaction of type I receptors of the TGF - beta family with the immunophilin FKBP12. Science, 1999,265(5172) : 674 - 676.
6Chamienia A,Biedunkiewicz B, Kr61 E, et al. One - year observation of kidney allograft recipients converted from cyclosporine microemulsion to tacrolimus, transplantation Proc, 2006,38 ( 1 ) : 81 - 85.
7Allison AC. Mechanisms of action of mycophenolate mofetil in preventing chronic rejection. Transplant Proc, 2002, 34 (7): 2863 - 2866.
8Pescovitz MD, Conti D, Dunn J, et al. Intravenous mycophenolate mofetil: safety, tolerability, and pharmacokinetics. Clin Transplant,2000,14(3):179 - 188.
9Yashima Y, Ohagane T. Pharmacological profiles of mycophenolate mofetil (CellCept), a new immunosuppressive agent. Nippon Yakurigaku Zasshi,2001,117(2) : 131 - 137.
10Ponticelli C. The pleiotropic effects of mTOR inhibitors. J Nephrol, 2004,17(6) : 762 - 768.
6Seron D. Early diagnosis of chronic allograft nephropathy by means of protocol biopsies [ J ]. Transplant Proc, 2004,36 (3) :763-764.
7Morard I, Dumortier J, Spahr I, et al. Conversion to sirolimusbased immunosuppression in maintenance liver transplantation patients [ J ]. Liver transpl, 2007,13 (5) :658-664.
8Meier M, Nitschke M, Weidtmann B, et al. Slowing the progression of chronic allograft nephropathy by conversion from cyclosporine to tacrolimus: a randomized controlled trial [ J ]. Transplantation, 2006,81(7) :1035-1040.
9Ekberg H, Tedesco-Silva H, Demirbas A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation [J].N Engl J Med, 2007,35 ( 25 ) :2562-2575.
10Ekberg H, Grinyo J, Nashan B, et al. Cyelosporinc sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: the CAESAR Study [J]. Am J Transplant, 2007,7 ( 3 ) :560-570.
